IFN Regulatory Factor 5 Is Required for Disease Development in the FcγRIIB−/−Yaa and FcγRIIB−/− Mouse Models of Systemic Lupus Erythematosus
Open Access
- 27 December 2009
- journal article
- Published by The American Association of Immunologists
- Vol. 184 (2), 796-806
- https://doi.org/10.4049/jimmunol.0901748
Abstract
Polymorphisms in the transcription factor IFN regulatory factor 5 (IRF5) are strongly associated in human genetic studies with an increased risk of developing the autoimmune disease systemic lupus erythematosus. However, the biological role of IRF5 in lupus pathogenesis has not previously been tested in an animal model. In this study, we show that IRF5 is absolutely required for disease development in the FcγRIIB−/−Yaa and FcγRIIB−/− lupus models. In contrast to IRF5-sufficient FcγRIIB−/−Yaa mice, IRF5-deficient FcγRIIB−/−Yaa mice do not develop lupus manifestations and have a phenotype comparable to wild-type mice. Strikingly, full expression of IRF5 is required for the development of autoimmunity, as IRF5 heterozygotes had dramatically reduced disease. One effect of IRF5 is to induce the production of the type I IFN, IFN-α, a cytokine implicated in lupus pathogenesis. To address the mechanism by which IRF5 promotes disease, we evaluated FcγRIIB−/−Yaa mice lacking the type I IFN receptor subunit 1. Unlike the IRF5-deficient and IRF5-heterozygous FcγRIIB−/−Yaa mice, type I IFN receptor subunit 1-deficient FcγRIIB−/−Yaa mice maintained a substantial level of residual disease. Furthermore, in FcγRIIB−/− mice lacking Yaa, IRF5-deficiency also markedly reduced disease manifestations, indicating that the beneficial effects of IRF5 deficiency in FcγRIIB−/−Yaa mice are not due only to inhibition of the enhanced TLR7 signaling associated with the Yaa mutation. Overall, we demonstrate that IRF5 plays an essential role in lupus pathogenesis in murine models and that this is mediated through pathways beyond that of type I IFN production.Keywords
This publication has 87 references indexed in Scilit:
- Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studiesNature Reviews Genetics, 2009
- Association of the IRF5 risk haplotype with high serum interferon‐α activity in systemic lupus erythematosus patientsArthritis & Rheumatism, 2008
- A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosisProceedings of the National Academy of Sciences, 2008
- Control of Toll-like Receptor 7 Expression Is Essential to Restrict Autoimmunity and Dendritic Cell ProliferationImmunity, 2007
- Deficiency of the type I interferon receptor protects mice from experimental lupusArthritis & Rheumatism, 2007
- The IRF family, revisitedBiochimie, 2007
- High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosusGenes & Immunity, 2007
- Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppressionProceedings of the National Academy of Sciences, 2007
- Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of LupusImmunity, 2006
- ATlr7translocation accelerates systemic autoimmunity in murine lupusProceedings of the National Academy of Sciences, 2006